New cervical cancer diagnosis (OmniPlex-HPV) obtained approval from the Ministry of Food and Drug Safety
작성일 17-02-16 13:29
On February 15th, Genematrix's subsidiary, HBI Co., Ltd., obtained approval for manufacturing products from the Ministry of Food and Drug Safety for OmniPlex-HPV, a new cervical cancer diagnosis product of Genematrix.
This product is a 40 kinds of human papillomavirus (HPV) genotyping kit based on Bead Microarray, and is a next-generation molecular diagnosis product that is fused with the MAGPIX system of Luminex, USA. It is designed to diagnose 40 types of HPV genotypes within 1 day.
The company is expected to greatly contribute to the expansion of domestic demand and exports in the future.